Medifocus, Inc. (OTCQX: MDFZF) develops and commercializes
minimally invasive treatment systems used in the treatment of cancerous and
benign tumors, specifically Benign Prostatic Hyperplasia (BPH). With two
technology platforms and approximately 100 issued and pending patents, the
company is addressing a vital niche in the medical industry. According to a
study by the National Center for Biotechnology Information, a strong majority
of men will develop histologic features consistent with BPH at some point in
their lives. While just 10 percent of men in their 30s display these features,
the prevalence rises with age, climbing to 90 percent for men in their 70s.
Prolieve®, Medifocus’s proprietary BPH treatment solution,
is a revenue-generating product catering to a multi-billion dollar market.
Considered a true in-office therapy by urologists because of its immediate
symptom relief, Prolieve® is currently in use by a network of nearly 250
physicians nationwide. In August 2014, Medifocus restructured the costs associated
with Prolieve® sales to improve operational efficiency, and the initial results
have been promising.
“Since we launched the Prolieve® restructuring program, we
have reduced our operating costs and are seeing immediate but gradual recovery
in revenue,” stated Dr. Augustine Cheung, Chief Executive Officer of Medifocus.
“We will remain diligently focused on minimizing our operating expenses… in our
effort to grow the Prolieve® business in a more efficient and sustainable
manner.”
In addition to BPH, Medifocus has recently turned its
attention toward breast cancer through the development of its APA 1000
treatment system. The system works by providing volumetric heating to treat
large, solid tumors, and it is approved by the FDA for use with radiation
therapy. Currently, Medifocus is working to accelerate APA 1000’s Phase III
clinical study. When completed, the new treatment method will open the door to
a vital sector of the medical industry. According to Breastcancer.org, breast
cancer affects approximately 12 percent of women, and an estimated 231,840 new
cases of invasive breast cancer are expected to be diagnosed in women in the
United States in 2015.
Through continued development and advancement of its
treatment technologies, Medifocus has strategically positioned itself for
strong returns moving forward. In the final quarter of 2014, Medifocus realized
a 40 percent increase in sales over the previous quarter, providing a glimpse
of the massive potential for growth the company’s proprietary technologies
could offer moving forward. These results, in addition to a recently announced
option agreement with Duke University regarding heat-activated and tumor
targeted immunotherapy, should provide Medifocus with an opportunity to realize
sustained growth in the years to come.
For more information, visit www.medifocusinc.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment